Barings LLC continued to hold its position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,700 shares of the specialty pharmaceutical company’s stock at the close of the second quarter. Barings LLC’s holdings in SciClone Pharmaceuticals were worth $173,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of SCLN. GLG Partners LP boosted its stake in SciClone Pharmaceuticals by 337.5% in the 2nd quarter. GLG Partners LP now owns 1,588,897 shares of the specialty pharmaceutical company’s stock worth $17,478,000 after purchasing an additional 1,225,709 shares during the period. Renaissance Technologies LLC boosted its stake in SciClone Pharmaceuticals by 21.9% in the 2nd quarter. Renaissance Technologies LLC now owns 2,540,200 shares of the specialty pharmaceutical company’s stock worth $27,942,000 after purchasing an additional 456,100 shares during the period. GAM Holding AG acquired a new position in SciClone Pharmaceuticals in the 2nd quarter worth approximately $4,261,000. Athos Capital Ltd acquired a new position in SciClone Pharmaceuticals in the 2nd quarter worth approximately $3,126,000. Finally, Vanguard Group Inc. boosted its stake in SciClone Pharmaceuticals by 9.2% in the 1st quarter. Vanguard Group Inc. now owns 2,948,846 shares of the specialty pharmaceutical company’s stock worth $28,899,000 after purchasing an additional 248,785 shares during the period. 72.80% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Barings LLC Maintains Holdings in SciClone Pharmaceuticals, Inc. (SCLN)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/10/21/barings-llc-maintains-holdings-in-sciclone-pharmaceuticals-inc-scln.html.

In other news, VP Lan Xie sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the transaction, the vice president now owns 10,000 shares in the company, valued at $110,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Hong Zhao sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $330,000.00. Following the completion of the transaction, the chief executive officer now owns 30,000 shares of the company’s stock, valued at approximately $330,000. The disclosure for this sale can be found here. 5.16% of the stock is currently owned by insiders.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) opened at 11.15 on Friday. The company has a 50-day moving average of $11.10 and a 200-day moving average of $10.55. SciClone Pharmaceuticals, Inc. has a 1-year low of $8.55 and a 1-year high of $11.43. The firm has a market cap of $581.93 million, a price-to-earnings ratio of 13.75 and a beta of 1.72.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.02. The firm had revenue of $44.52 million during the quarter. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. Analysts predict that SciClone Pharmaceuticals, Inc. will post $0.94 earnings per share for the current year.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.